A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

Summary

The purpose of this Phase 1 study is to determine if AMG 211 given as a continous intravenous (IV) infusion is safe and tolerable in adult participants that have advanced gastrointestinal adenocarcinoma. The study will be conducted in multiple sites and test increasing doses of AMG 211. The safety of participants will be monitored by intensive assessment of vital signs, electrocardiograms, physical examinations, and laboratory tests. Efficacy will be assessed by the usual imaging procedures and their interpretation.

Timeline

Start

2014-11-27

Primary completion

2017-11-06

Completion

2018-01-09

Outcome

Outcome not reported

Stopped (Business): “The study was terminated because of immunogenicity and business decision.”

Drugs

Indications